Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm Technologies (NASDAQ: IRTC) has successfully closed its underwritten public offering of 1,257,142 shares at $175.00 each, totaling approximately $220 million in gross proceeds. This includes the full exercise of underwriters' options for an additional 163,975 shares. J.P. Morgan and Morgan Stanley led the offering, with Citigroup and others as co-managers. Investors can access the final prospectus on the SEC website. iRhythm focuses on innovative cardiac care solutions, utilizing wearable biosensors and cloud analytics to enhance arrhythmia diagnosis.
iRhythm Technologies (NASDAQ: IRTC) has announced the pricing of an underwritten public offering of 1,093,167 shares at $175.00 per share, aiming to raise approximately $191.3 million. The offering includes a 30-day option for underwriters to purchase an additional 163,975 shares. The funds will support growth initiatives, working capital, and potential expansions, such as enhancing their sales force and increasing R&D activities. The offering is set to close on August 21, 2020, pending customary conditions.
iRhythm Technologies, Inc. (NASDAQ: IRTC) has initiated a public offering of 1,000,000 shares of common stock, with an option for underwriters to purchase an additional 150,000 shares. The proceeds will fund growth initiatives, expand the sales force and operations, enhance R&D activities, and support general corporate purposes. The offering is subject to market conditions, and there are no current agreements for acquisitions. The registration statement has been filed with the SEC but is not yet effective.
iRhythm Technologies, Inc. (NASDAQ: IRTC) reported a 3% decline in revenue for Q2 2020, totaling $50.9 million, compared to $52.4 million in Q2 2019. Gross margin decreased to 69.6% from 75.2% year-over-year, with operating expenses rising 11.1% to $55.6 million. The net loss widened to $20.4 million or $0.75 per share, versus a loss of $10.7 million or $0.43 per share in the prior year. The company has not provided full-year guidance due to ongoing COVID-19 uncertainties.
iRhythm Technologies (NASDAQ: IRTC) is set to host a conference call on August 4, 2020, at 1:10 PM PT to discuss the impact of new Medicare codes on its business, as outlined in the 2021 Medicare Physician Fee Schedule Proposed Rule. The event will be available via live and archived webcast on the company’s investor website. iRhythm specializes in digital health care solutions for diagnosing cardiac arrhythmias, using advanced biosensor devices and proprietary algorithms.
iRhythm Technologies is set to present at the 40th Annual Canaccord Genuity Global Growth Conference on August 13, 2020, at 11:30 a.m. ET in Boston, MA. The company specializes in digital health solutions for cardiac care, utilizing wearable biosensor devices and advanced cloud-based analytics for arrhythmia diagnosis. Interested participants can access the live and archived webcast through the company's website. This conference represents a significant opportunity for iRhythm to showcase its innovative approaches to cardiac health diagnostics.
iRhythm Technologies (NASDAQ: IRTC) has announced it will release its Q2 2020 financial results after market close on August 6, 2020. The management team will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via a live and archived webcast on the company’s website.
iRhythm is recognized for its innovative approach to cardiac care, utilizing wearable biosensors and cloud-based analytics to enhance arrhythmia detection.
Summary not available.